The impact of androgen receptor expression on breast cancer survival: a retrospective study and meta-analysis.
The impact of androgen receptor expression on breast cancer survival: a retrospective study and meta-analysis.
复制标题
DOI：
10.1371/journal.pone.0082650
复制
发表时间：
2013
期刊：
影响因子：
3.7
通讯作者：
Shen KW
中科院分区：
文献类型：
--
作者：
Qu Q;Mao Y;Fei XC;Shen KW
最近的研究强调了雄激素受体（AR）作为乳腺癌预后生物标志物的作用。然而，其对无病生存期（DFS）和总生存期（OS）的预测作用仍然没有定论。本研究旨在回顾性研究AR与乳腺癌生存结局之间的相关性，并通过对已发表研究的荟萃分析确定这种相关性。采用组织芯片技术对109例乳腺癌患者的临床资料进行回顾性分析。对于荟萃分析，纳入了Pubmed中关于AR与乳腺癌结局之间关系的文章。从两者获得的数据进行了合并和分析。在回顾性研究中，AR阳性肿瘤女性的DFS（HR 0.24，95% CI 0.07-0.88）和OS（HR 0.19，95% CI 0.04-0.85）显著优于AR阴性女性。Meta分析显示，乳腺肿瘤中AR表达是DFS较好的指标（HR 0.52，95% CI 0.43-0.64）。在亚组分析中，AR可预测雌激素受体（ER）阳性（HR 0.45，95% CI 0.34-0.59）、ER阴性（HR 0.42，95% CI 0.26-0.67）和三阴性乳腺癌（HR 0.40，95% CI 0.23-0.69）的DFS结局。在ER阳性乳腺癌患者中，AR的表达能更好地预测OS（HR 0.39，95% CI 0.19-0.82）。目前的分析表明，AR表达与所有类型乳腺癌患者的复发风险降低和ER阳性病例的OS更好相关。
Recent studies have highlighted the role of androgen receptor (AR) as a prognostic biomarker of breast cancer. However, its predictive role in disease free survival (DFS) and overall survival (OS) still remains inconclusive. The present study aimed to retrospectively investigate the association between AR and survival outcomes in breast cancer and also identify this association by a meta-analysis of published researches. Clinical data from 109 patients with breast cancer, who underwent surgery at Ruijin Hospital, Shanghai, were retrospectively analyzed for immunohistochemical AR expression measured by tissue microarray. For meta-analysis, articles available in Pubmed on the relationship between AR and breast cancer outcomes were included. Data obtained from both were combined and analyzed. Women with AR positive tumors in the retrospective study had a significantly better DFS (HR 0.24, 95% CI 0.07-0.88) and OS (HR 0.19, 95% CI 0.04-0.85) than women with AR negative ones. Meta-analysis showed that AR expression in breast tumors was an indicator of better DFS (HR 0.52, 95% CI 0.43-0.64). In subgroup analysis, AR could predict DFS outcome in estrogen receptor (ER) positive (HR 0.45, 95% CI 0.34-0.59), ER negative (HR 0.42, 95% CI 0.26-0.67), and triple negative breast cancer (HR 0.40, 95% CI 0.23-0.69). Moreover, in ER positive breast cancer patients, the expression of AR could predict better OS (HR 0.39, 95% CI 0.19-0.82). The present analysis indicated that AR expression was associated with lower risk of recurrence in patients with all breast cancer types and better OS in cases with ER positive.
登录
查看更多内容
DOI：
10.1186/bcr2858
发表时间：
2011-04-01
期刊：
Breast cancer research : BCR
影响因子：
--
作者：
Naderi A;Chia KM;Liu J
通讯作者：
Liu J
绝经后妇女的雄激素受体表达和乳腺癌存活。
DOI：
10.1158/1078-0432.ccr-10-2021
发表时间：
2011-04-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Hu R;Dawood S;Holmes MD;Collins LC;Schnitt SJ;Cole K;Marotti JD;Hankinson SE;Colditz GA;Tamimi RM
通讯作者：
Tamimi RM
影响因子：
3.8
作者：
Gonzalez LO;Corte MD;Vazquez J;Junquera S;Sanchez R;Alvarez AC;Rodriguez JC;Lamelas ML;Vizoso FJ
通讯作者：
Vizoso FJ
影响因子：
50.5
作者：
Park, S.;Koo, J. S.;Lee, K. S.
通讯作者：
Lee, K. S.
影响因子：
3.8
作者：
Castellano, Isabella;Allia, Elena;Sapino, Anna
通讯作者：
Sapino, Anna